U.S. markets closed

Imagin Medical Inc. (IMEXF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1527-0.0004 (-0.26%)
At close: 03:36PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1531
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1527 - 0.1973
52 Week Range0.1200 - 0.4400
Avg. Volume8,229
Market Cap1.654M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IMEXF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    ORLY: Lowering target price to $889.00O'REILLY AUTOMOTIVE INC has an Investment Rating of HOLD; a target price of $889.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • PR Newswire

    Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

    Ponce Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, announced today that it had executed a worldwide, exclusive license to Speratum's proprietary Nano-in™ and No-Pass Mimic™ technologies to advance its lead product, ReBeaut™, a state-of-the-art biotechnology platform to restore the youthful balance of aged or "senescent" and young, vital cells in the skin, targeting the senescent cells for elimination,

  • PR Newswire

    Imagin Medical Announces Stock Option Grants

    Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 472,187 shares have been granted to certain employees, board members and consultants as incentive stock options at an exercise price of $0.28 USD per share. The options are exercisable for a period of five years, ending on April 22, 2027.